HomeProductsBioactive CompoundsNeuronal SignalingAmyloid-??Avagacestat
Chemical structure of CAS 1146699-66-2

Avagacestat

CAS No.1146699-66-2
MDL No.N/A
MFC20H17ClF4N4O4S
MW520.90
InChI KeyXEAOPVUAMONVLA-QGZVFWFLSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Avagacestat is an oxadiazole with a ring assembly structure.

CAS No.1146699-66-2
Product NameAvagacestat
IrritantIrritant
Signal Word:Warning
HCode:H315-H319-H335
PCode:P261-P264-P264+P265-P271-P280-P302+P352-P304+P340-P305+P351+P338-P319-P321-P332+P317-P337+P317-P362+P364-P403+P233-P405-P501

Related Articles

Studies related to this compound and its mechanism of action

Investigations on the Relationship Between Ovarian, Endocrine, and Renal Findings in Nonclinical Safety Studies of the γ-Secretase Inhibitor Avagacestat.

Toxicological sciences : an official journal of the Society of Toxicology • Vol. 171, Issue 1 • 2019
PMID: 31165171DOI: 10.1093/toxsci/kfz129

Nonclinical Safety Assessment of the γ-Secretase Inhibitor Avagacestat.

Toxicological sciences : an official journal of the Society of Toxicology • Vol. 163, Issue 2 • 2018
PMID: 29529279DOI: 10.1093/toxsci/kfy048

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.

Archives of neurology • Vol. 69, Issue 11 • 2012
PMID: 22892585DOI: 10.1001/archneurol.2012.2194

Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as γ-secretase inhibitors.

Journal of medicinal chemistry • Vol. 54, Issue 22 • 2011
PMID: 21995460DOI: 10.1021/jm200893p

Documentation